Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections

Vick-Fragoso, Rodolfo; Hernández-Oliva, Gerardo; Cruz-Alcázar, J.; Amábile-Cuevas, Carlos F.; Arvis, Pierre; Reimnitz, Peter; Bogner, Johannes R.

doi:10.1007/s15010-009-8468-x

Cited by 55 publications

(53 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previously reported studies and case reports, MXF has been shown to be successful for the treatment of abscesses of other origins, e.g., skin (26) and abdominal cavity (16).…”

Section: Discussionmentioning

confidence: 92%

Comparative Efficacy and Safety of Moxifloxacin and Clindamycin in the Treatment of Odontogenic Abscesses and Inflammatory Infiltrates: a Phase II, Double-Blind, Randomized Trial

Cachovan

Böger

Giersdorf

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…According to previously reported studies and case reports, MXF has been shown to be successful for the treatment of abscesses of other origins, e.g., skin (26) and abdominal cavity (16).…”

Section: Discussionmentioning

confidence: 92%

Comparative Efficacy and Safety of Moxifloxacin and Clindamycin in the Treatment of Odontogenic Abscesses and Inflammatory Infiltrates: a Phase II, Double-Blind, Randomized Trial

Cachovan

Böger

Giersdorf

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…For diabetic foot infection as well as for necrotizing fasciitis the lowest clinical cure rates of 232 skin and skin-structure infections are reported [11]. Of the fluoroquinolones licensed, 233 moxifloxacin is the only one demonstrating activity against anaerobe pathogens.…”

Section: Discussion 231mentioning

confidence: 99%

“…In this patient population, the tissue to plasma ratio was 0. 11,16]. In a recent prospective, randomized, multinational clinical 323 study treatment with sequential IV/PO moxifloxacin, 400 mg once daily was clinically 324 comparable to that with IV amoxicillin/clavulanate 1,000 mg/ 200 mg three times daily 325 followed by PO amoxicillin/clavulanate 500 mg/125 mg three times daily for 7-21 days in 326 hospitalized patients with cSSSIs [11].…”

mentioning

confidence: 99%

Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort

Majcher-Peszynska

Saß

Schipper

et al. 2010

Eur J Clin Pharmacol

View full text Add to dashboard Cite

“…Accordingly, some authors have found better clinical response in patients who received beta-lactams, even without MRSA cover, compared to quinolones or other broad-spectrum antibiotics 14 . However, a double-blind study comparing amoxicillin-clavulanate with moxifloxacin, initially administered intravenously and then orally, did not find any differences 15 .…”

Section: Discussionmentioning

confidence: 92%

“…The microorganism was recovered more frequently among patients with abscess (15% vs 8%) or cSSTI (56% vs 25%) than in patients with uncomplicated cellutitis (29% vs 67%, p = 0.001). Patients with positive microbiology results had longer duration of treatment (median [IQR]: 18 [15-29.5] vs 15 [12][13][14][15][16][17][18][19] days, p = 0.003) and longer hospital stay (11 [7][8][9][10][11][12][13][14][15][16][17] vs 8 [5][6][7][8][9][10][11][12][13] days, p = 0.014).…”

Section: Discussionmentioning

confidence: 99%

Tratamiento empírico de pacientes ingresados con infección de piel y partes blandas: ¿cómo lo estamos haciendo?

Pérez-Rodríguez¹,

Argibay²,

Nodar³

et al. 2014

Gal. Clin.

View full text Add to dashboard Cite

ResumenObjetivos: Existen diferentes guías de tratamiento de la infección de piel y partes blandas (IPPB), sin embargo el tratamiento de estos pacientes es muy variable. Los objetivos fueron analizar las pautas antibióticas, así como su duración en pacientes con IPPB que precisaron ingreso. Pacientes y métodos: Se revisaron los pacientes con IPPB ingresados entre enero y diciembre de 2009. Se recogieron las pautas de tratamiento antibiótico empleadas antes, durante y tras el ingreso, así como su duración. Resultados: De un total de 131 pacientes con IPPB ingresados, se identificaron 41 pautas diferentes de tratamiento antibiótico. En 61 pacientes (47%) se emplearon dos o más fármacos y en 21 (16%) antibióticos de amplio espectro. En 25 pacientes (19%) se modificó la pauta antibiótica por mala evolución y se utilizaron 16 regímenes antibióticos diferentes. En los pacientes con fracaso del tratamiento antibiótico, ni la duración del ingreso (12 ± 9.0 días vs. 14 ± 8.7 días, p = 0.31), ni la duración del tratamiento antibiótico (12 ± 8.2 días vs. 14 ± 6.8 días, p = 0.33) fueron superiores a la de aquellos en los que la respuesta al tratamiento empírico inicial fue adecuada. Al alta, 95 pacientes (73%) recibieron tratamiento antibiótico, se identificaron 25 regímenes diferentes; 22 pacientes (23%) recibieron dos o más antibióticos y antibióticos de amplio espectro se pautaron en 10 casos. Conclusiones: La IPPB es una causa creciente de hospitalización y, a pesar de existir guías recientes de tratamiento, las pautas de tratamiento antibiótico son altamente variables. Palabras clave: Celulitis; infección de piel y partes blandas; absceso cutáneo; tratamiento antibiótico. AbstractObjetives: There are several clinical guidelines for the management of skin and soft tissue infections (SSTI); however, the empirical treatment of patients with this common cause of hospital admission is highly variable. The aims of this study were to determine the empirical antibiotic treatment regimes and the duration of antibiotic treatment of SSTI requiring hospitalization. Patients and methods: Cases admitted for SSTI were reviewed. We evaluated antibiotic therapy before, during and after hospitalization, as well as duration of treatment. Results: From the 131 patients, 41 different antibiotic regimes were identified. Antibiotic combinations were used in 61 patients (47%) and broadspectrum antibiotics were used in 21 patients (16%). Modification of the antibiotic regimen was required in 25 patients (19%) due to poor clinical response, and 16 different regimes were prescribed. For patients with treatment failure, neither duration of hospitalization (12 ± 9.0 days vs. 14 ± 8.7 days, p = 0.31) nor duration of antibiotic treatment (12 ± 8.2 days vs. 14 ± 6.8 days, p = 0.33) were greater than for those who responded to the initial empirical treatment. On discharge, antibiotic treatment was prescribed for 95 patients (73%), with 25 different regimes, including a combination of drugs in 22 patients (23%) and broad-spectrum antibiotics in 10. Con...

show abstract

Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections

Cited by 55 publications

References 16 publications

Comparative Efficacy and Safety of Moxifloxacin and Clindamycin in the Treatment of Odontogenic Abscesses and Inflammatory Infiltrates: a Phase II, Double-Blind, Randomized Trial

Comparative Efficacy and Safety of Moxifloxacin and Clindamycin in the Treatment of Odontogenic Abscesses and Inflammatory Infiltrates: a Phase II, Double-Blind, Randomized Trial

Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort

Tratamiento empírico de pacientes ingresados con infección de piel y partes blandas: ¿cómo lo estamos haciendo?

Contact Info

Product

Resources

About